{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:13:58Z","timestamp":1793319238258,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajpc.2025.101067","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T15:19:34Z","timestamp":1753283974000},"page":"101067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Real-world prescribing in accordance to ACC\/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1185-555X","authenticated-orcid":false,"given":"Jonathan","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetal","family":"Boricha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himal","family":"Chapagain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleesha","family":"Kainat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hyeon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad B.","family":"Ateya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"DeMicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Alish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Becich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia H.","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad A.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenke","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Lester","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Paranjape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozelle","family":"Hegeman-Dingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euan","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip A.","family":"Saccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"McTigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ajpc.2025.101067_bib0001","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"8934","key":"10.1016\/j.ajpc.2025.101067_bib0002","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ajpc.2025.101067_bib0003","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.ajpc.2025.101067_bib0004","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.ajpc.2025.101067_bib0005","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"9753","key":"10.1016\/j.ajpc.2025.101067_bib0006","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL-C cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ajpc.2025.101067_bib0007","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2165\/11638240-000000000-00000","article-title":"Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis","volume":"72","author":"de Vries","year":"2012","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101067_bib0008","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.numecd.2022.07.018","article-title":"Statin use and the risk of CVD events, stroke, and all-cause mortality in patients with diabetes: a systematic review and meta-analysis","volume":"32","author":"Yang","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"20","key":"10.1016\/j.ajpc.2025.101067_bib0009","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"NEJM"},{"issue":"20","key":"10.1016\/j.ajpc.2025.101067_bib0010","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","article-title":"Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg\/dL or above","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ajpc.2025.101067_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009517","article-title":"High-intensity versus non-high-intensity statins in patients achieving low-density lipoprotein cholesterol goal after percutaneous coronary intervention","volume":"7","author":"Kim","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101067_bib0012","article-title":"Lipid-lowering for peripheral arterial disease of the lower limb","volume":"2007","author":"Aung","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"10.1016\/j.ajpc.2025.101067_bib0013","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.3390\/jcm11226825","article-title":"Cardiovascular risk profile and lipid management in the population-based cohort study LATINO: 20 years of real-world data","volume":"11","author":"Gavina","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajpc.2025.101067_bib0014","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2147\/RMHP.S358015","article-title":"Evaluation of the therapeutic pattern and pharmaco-utilization in hypercholesterolemic patients treated with statins: a retrospective study on Italian real-world data","volume":"15","author":"Perrone","year":"2022","journal-title":"Risk Manag Healthc Policy"},{"issue":"18","key":"10.1016\/j.ajpc.2025.101067_bib0015","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101067_bib0016","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/1074248419899298","article-title":"Lipid-lowering therapy and low-density lipoprotein cholesterol (LDL-C) goal achievement in high-cardiovascular-risk patients in Fuzhou, China","volume":"25","author":"Wang","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ajpc.2025.101067_bib0017","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/dom.14364","article-title":"Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: real-world evidence from primary care","volume":"23","author":"Ling","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajpc.2025.101067_bib0018","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","article-title":"Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany","volume":"268","author":"M\u00e4rz","year":"2018","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.ajpc.2025.101067_bib0019","first-page":"892","article-title":"Antihyperlipidemic medication treatment patterns and statin adherence among patients with ASCVD in a managed care plan after release of the 2013 ACC\/AHA guideline on the treatment of blood cholesterol","volume":"22","author":"Bellows","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101067_bib0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jacc.2015.05.030","article-title":"Utilization of and adherence to guideline-recommended lipid-lowering therapy after acute coronary syndrome: opportunities for improvement","volume":"66","author":"Hirsh","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101067_bib0021","article-title":"Cardiovascular disease risk\u2013based statin utilization and associated outcomes in a primary prevention cohort: insights from a large health care network","volume":"14","author":"Saeed","year":"2021","journal-title":"Circul: Cardiovasc Qual Outcomes"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101067_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010376","article-title":"Adherence to statin therapy among US adults between 2007 and 2014","volume":"8","author":"Colantonio","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101067_bib0023","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/PPA.S245365","article-title":"Reasons for nonadherence to statins \u2013 A systematic review of reviews","volume":"14","author":"Ingersgaard","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"10.1016\/j.ajpc.2025.101067_bib0024","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.amjcard.2019.07.002","article-title":"Lipid-lowering prescription patterns in patients with diabetes mellitus or cardiovascular disease","volume":"124","author":"Chamberlain","year":"2019","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.ajpc.2025.101067_bib0025","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.amjcard.2016.08.065","article-title":"Decade-long trends (2001 to 2011) in the use of evidence-based medical therapies at the time of hospital discharge for patients surviving acute myocardial infarction","volume":"118","author":"Makam","year":"2016","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101067_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001891","article-title":"Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus","volume":"9","author":"Garc\u00eda-Ulloa","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101067_bib0027","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40119-021-00240-8","article-title":"Real-world evidence for adherence and persistence with atorvastatin therapy","volume":"10","author":"Tsioufis","year":"2021","journal-title":"Cardiol Ther"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101067_bib0028","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1060028018792702","article-title":"Adherence to and persistence with statin therapy in a veteran population","volume":"53","author":"Morotti","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101067_bib0029","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011246","article-title":"PCSK9 inhibitor use in the real world: data from the National Patient-Centered Research Network","volume":"8","author":"Chamberlain","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"10.1016\/j.ajpc.2025.101067_bib0030","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2025.101067_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100336","article-title":"Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update","volume":"10","author":"Gu","year":"2022","journal-title":"Am J Prev Cardiol"},{"issue":"100921","key":"10.1016\/j.ajpc.2025.101067_bib0032","article-title":"Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cvMOBIUS2 registry","volume":"21","author":"Shoji","year":"2025","journal-title":"Am J Prev Cardiol"},{"issue":"14","key":"10.1016\/j.ajpc.2025.101067_bib0033","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"80","author":"Lloyd-Jones Donald","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101067_bib0034","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11606-014-3102-8","article-title":"Accuracy of race, ethnicity, and language preference in an electronic health record","volume":"30","author":"Klinger","year":"2015","journal-title":"J Gen Intern Med"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725001424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725001424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T21:01:27Z","timestamp":1760648487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667725001424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"alternative-id":["S2666667725001424"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101067","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world prescribing in accordance to ACC\/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101067"}}